Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Novo Nordisk A/S — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.48, while Novo Nordisk A/S trades at $51.58 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals.
| EMLC | NVO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $71.70 |
52-Week Low | $24.83 | $35.29 |
Market Cap | — | $222.24B |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47, showing minimal daily movement with a slight decline of 0.04%. Technical indicators signal a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share throughout 2026, providing steady income. Recent news highlights growing institutional interest in emerging market bonds as investors seek yield above Treasury rates.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market debt's attractive yield premium. However, currency risk and capital erosion concerns persist as short interest has surged 73%, indicating skepticism about long-term sustainability despite the 6.1% trailing yield.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
